RECRUITING

Patient Derived Preclinical Models

Talk to us

Conditions

Cancer

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Study goal is to collect tumor specimens that may inform cancer biology to eventually improve outcomes for patients with cancer. This proposal represents a highly collaborative effort to support cancer research with the goal of developing novel therapeutic strategies using patient derived preclinical models. This study is being done to collect samples of tumor tissues, matched normal tissue when possible, and approximately 50 mL of blood.

Official Title

Patient Derived Preclinical Models

Quick Facts

Study Start:2022-04-06
Study Completion:2028-03-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05324553

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * 18 years of age and older
  2. * Patient is a good medical candidate for a standard of care or research biopsy or surgical procedure to obtain tissue
  1. * Uncontrolled concurrent illness including psychiatric illness, or situations that would limit compliance with the study requirements or the ability to willingly give written informed consent
  2. * Institutionalized or incarcerated patients
  3. * Inaccessible tumor for biopsy or patient does not have tumor tissue available for research use
  4. * Biopsy must not be considered more than minimal risk to the patient.
  5. * Have a contraindication to percutaneous biopsy including:
  6. 1. Significant coagulopathy that cannot be adequately corrected.
  7. 2. Severely compromised cardiopulmonary function or hemodynamic instability.
  8. 3. Lack of a safe pathway to the lesion per the interventional radiologist.
  9. 4. Inability of the patient to cooperate with, or to be positioned for, the procedure.

Contacts and Locations

Study Contact

Clinical Trials Referral Office
CONTACT
855-776-0015
mayocliniccancerstudies@mayo.edu
Tanya M. Schnick
CONTACT
507 293-7582
Schnick.Tanya@mayo.edu

Principal Investigator

Aaron S. Mansfield, M.D.
PRINCIPAL_INVESTIGATOR
Mayo Clinic

Study Locations (Sites)

Mayo Clinic in Rochester
Rochester, Minnesota, 55905
United States

Collaborators and Investigators

Sponsor: Mayo Clinic

  • Aaron S. Mansfield, M.D., PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-04-06
Study Completion Date2028-03-31

Study Record Updates

Study Start Date2022-04-06
Study Completion Date2028-03-31

Terms related to this study

Keywords Provided by Researchers

  • Cancer

Additional Relevant MeSH Terms

  • Cancer